Dr. Satoh is the Global MA Head, Executive Officer, and Director of Medical Affairs of Kyowa Kirin Co., Ltd., where he has held scientific staff and leadership positions since 1987. In 2017, he was appointed Executive Officer, Vice President, and Head of Research & Development Division. Prior to these roles, he served as the Director of the Immunology & Allergy Research & Development Unit and the Deputy Director of the Strategic Product Portfolio Department, Immunology Area.
In 1996, Dr. Satoh became a visiting scientist at the Texas Medical Center where he studied chromosome engineering and subsequently contributed to the development of Potelligent® Technology after returning to Japan. Dr. Satoh was involved in glyco-engineered biological pipeline developments, including Mogamulizumab, Benralizumab, and Acoalan.
Dr. Satoh holds a Master of Pharmacy and Ph.D. from Hokkaido University in Sapporo, Hokkaido, Japan. He received the Kei Arima Memorial Award from the Japan Bioindustry Association in 2005 and the 62nd Okochi Memorial Technology Prize from the Okochi Memorial Foundation in 2016.
